prikaz prve stranice dokumenta Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach
  Download
PDF 632.8 KB
Scientific paper - Original scientific paper
Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach
European Journal of Clinical Microbiology and Infectious Diseases, 40 (2021), 2; 261-268. https://doi.org/10.1007/s10096-020-04019-y
Rode, Oktavija Đaković; Kurolt, Ivan-Christian; Puljiz, Ivan; Čivljak, Rok; Balent, Nataša Cetinić; Laškaj, Renata; Tiljak, Mirjana Kujundžić; Mikulić, Radojka; Markotić, Alemka

Linked objects
COVID-19 | Virtual collection

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Rode, O. Đ., Kurolt, I. C., Puljiz, I., Čivljak, R., Balent, N. C., Laškaj, R. ... Markotić, A. (2021). Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach. European Journal of Clinical Microbiology and Infectious Diseases, 40. (2), 261-268. doi: 10.1007/s10096-020-04019-y

Rode, Oktavija Đaković, et al. "Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach." European Journal of Clinical Microbiology and Infectious Diseases, vol. 40, no. 2, 2021, pp. 261-268. https://doi.org/10.1007/s10096-020-04019-y

Rode, Oktavija Đaković, Ivan Christian Kurolt, Ivan Puljiz, Rok Čivljak, Nataša Cetinić Balent, Renata Laškaj, Mirjana Kujundžić Tiljak, Radojka Mikulić and Alemka Markotić. "Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach." European Journal of Clinical Microbiology and Infectious Diseases 40, no. 2 (2021): 261-268. https://doi.org/10.1007/s10096-020-04019-y

Rode, O. Đ., et al. (2021) 'Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach', European Journal of Clinical Microbiology and Infectious Diseases, 40(2), pp. 261-268. doi: 10.1007/s10096-020-04019-y

Rode OĐ, Kurolt IC, Puljiz I, Čivljak R, Balent NC, Laškaj R, and sur.. Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach. European Journal of Clinical Microbiology and Infectious Diseases [Internet]. 2021 February [cited 2024 April 23];40(2):261-268. doi: 10.1007/s10096-020-04019-y

O. Đ. Rode, et al., "Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach", European Journal of Clinical Microbiology and Infectious Diseases, vol. 40, no. 2, pp. 261-268, February 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:576675. [Accessed: 23 April 2024]

Metadata
Title (english)Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach
AuthorOktavija Đaković Rode
AuthorIvan-Christian Kurolt
AuthorIvan Puljiz
AuthorRok Čivljak
AuthorNataša Cetinić Balent
AuthorRenata Laškaj
AuthorMirjana Kujundžić Tiljak
AuthorRadojka Mikulić
AuthorAlemka Markotić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Infectious Diseases)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Infectology
Abstract (english)
According to anti-SARS-CoV-2 seroresponse in patients with COVID-19 from Croatia, we emphasised the issue of different serological tests and need for combining diagnostic methods for COVID-19 diagnosis. Anti-SARS-CoV-2 IgA and IgG ELISA and IgM/IgG immunochromatographic assay (ICA) were used for testing 60 sera from 21 patients (6 with severe, 10 moderate, and 5 with mild disease). The main clinical, demographic, and haemato-biochemical data were analysed. The most common symptoms were cough (95.2%), fever (90.5%), and fatigue and shortness of breath (42.9%). Pulmonary opacities showed 76.2% of patients. Within the first 7 days of illness, seropositivity for ELISA IgA and IgG was 42.9% and 7.1%, and for ICA IgM and IgG 25% and 10.7%, respectively. From day 8 after onset, ELISA IgA and IgG seropositivity was 90.6% and 68.8%, and for ICA IgM and IgG 84.4% and 75%, respectively. In general, sensitivity for ELISA IgA and IgG was 68.3% and 40%, and for ICA IgM and IgG 56.7% and 45.0%, respectively. The anti-SARS-CoV-2 antibody distributions by each method were statistically different (ICA IgM vs. IgG, p = 0.016; ELISA IgG vs. IgA, p < 0.001). Antibody response in COVID-19 varies and depends on the time the serum is taken, on the severity of disease, and on the type of test used. IgM and IgA antibodies as early-stage disease markers are comparable, although they cannot replace each other. Simultaneous IgM/IgG/IgA anti-SARS-CoV-2 antibody testing followed by the confirmation of positive findings with another test in a two-tier testing is recommended.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleEuropean Journal of Clinical Microbiology and Infectious Diseases
Numberingvol. 40, no. 2, pp. 261-268
p-ISSN0934-9723
e-ISSN1435-4373
DOIhttps://doi.org/10.1007/s10096-020-04019-y
URN:NBNurn:nbn:hr:184:576675
Publication2021-02
Document URLhttps://pubmed.ncbi.nlm.nih.gov/32886230/
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2020-10-04 18:56:09